^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Ivesa (furmonertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
Published date:
02/03/2023
Excerpt:
...we report a patient with advanced lung adenocarcinoma harboring an EGFR exon 20 insertion mutation (NM_005228: exon 20: c.2316_2321dup: p.773_774dup). After experiencing platinum-based chemotherapy, this patient received a combination of furmonertinib and anlotinib and achieved lasting stable disease (SD).
DOI:
https://doi.org/10.3389/fphar.2023.1053805
